[go: up one dir, main page]

WO2008139879A1 - Ｇ蛋白質共役型レセプター抑制剤および医薬 - Google Patents

Ｇ蛋白質共役型レセプター抑制剤および医薬 Download PDF

Info

Publication number
WO2008139879A1
WO2008139879A1 PCT/JP2008/057917 JP2008057917W WO2008139879A1 WO 2008139879 A1 WO2008139879 A1 WO 2008139879A1 JP 2008057917 W JP2008057917 W JP 2008057917W WO 2008139879 A1 WO2008139879 A1 WO 2008139879A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
coupled receptor
pharmaceutical product
receptor inhibitor
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/057917
Other languages
English (en)
French (fr)
Inventor
Gozo Tsujimoto
Akira Hirasawa
Naoki Miyata
Takayoshi Suzuki
Yoshiyuki Takahara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PHARMAFRONTIER Co Ltd
Original Assignee
PHARMAFRONTIER Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PHARMAFRONTIER Co Ltd filed Critical PHARMAFRONTIER Co Ltd
Priority to JP2009514078A priority Critical patent/JPWO2008139879A1/ja
Priority to US12/597,570 priority patent/US20100274022A1/en
Priority to EP08752016A priority patent/EP2154131A4/en
Publication of WO2008139879A1 publication Critical patent/WO2008139879A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Ｇ蛋白質共役型レセプターの活性化を抑制する物質および医薬を提供する。 Ｇ蛋白質共役型レセプター抑制剤は、 【化１】 で表される特定化合物を含んでいる。
PCT/JP2008/057917 2007-04-26 2008-04-24 Ｇ蛋白質共役型レセプター抑制剤および医薬 Ceased WO2008139879A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2009514078A JPWO2008139879A1 (ja) 2007-04-26 2008-04-24 Ｇ蛋白質共役型レセプター抑制剤および医薬
US12/597,570 US20100274022A1 (en) 2007-04-26 2008-04-24 G protein-coupled receptor inhibitor and pharmaceutical product
EP08752016A EP2154131A4 (en) 2007-04-26 2008-04-24 INHIBITOR OF THE G-PROTEIN-COUPLED RECEPTOR AND PHARMACEUTICAL PRODUCT

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-117458 2007-04-26
JP2007117458 2007-04-26

Publications (1)

Publication Number Publication Date
WO2008139879A1 true WO2008139879A1 (ja) 2008-11-20

Family

ID=40002095

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/057917 Ceased WO2008139879A1 (ja) 2007-04-26 2008-04-24 Ｇ蛋白質共役型レセプター抑制剤および医薬

Country Status (4)

Country Link
US (1) US20100274022A1 (ja)
EP (1) EP2154131A4 (ja)
JP (1) JPWO2008139879A1 (ja)
WO (1) WO2008139879A1 (ja)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010104195A1 (en) * 2009-03-11 2010-09-16 Banyu Pharmaceutical Co.,Ltd. Novel isoindolin-1-one derivative
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011161030A1 (de) 2010-06-21 2011-12-29 Sanofi Heterocyclisch substituierte methoxyphenylderivate mit oxogruppe, verfahren zu ihrer herstellung und ihre verwendung als gpr40 rezeptor modulatoren
WO2012004270A1 (de) 2010-07-05 2012-01-12 Sanofi Spirocyclisch substituierte 1,3-propandioxidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012004269A1 (de) 2010-07-05 2012-01-12 Sanofi ( 2 -aryloxy -acetylamino) - phenyl - propionsäurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012010413A1 (de) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylen-substituierte hydroxy-phenyl-hexinsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2014069963A1 (en) 2012-11-05 2014-05-08 Lg Life Sciences Ltd. Thioaryl derivatives as gpr120 agonists
JP2016527280A (ja) * 2013-08-09 2016-09-08 ファンダサウン オズワルド クルス ジフェニルオキシアルキルアミン誘導体およびアリールオキシアルキルアミン誘導体、薬学的組成物、慢性肺炎症性疾患を治療、予防、または阻止するための前記薬学的組成物の使用、ならびにそのような疾患を治療または予防するための方法
US10221138B2 (en) 2013-06-27 2019-03-05 Lg Chem, Ltd. Biaryl derivatives as GPR120 agonists
JPWO2021241659A1 (ja) * 2020-05-29 2021-12-02

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102076670B (zh) * 2008-06-24 2013-05-22 Irm责任有限公司 调节g蛋白偶联受体的化合物和方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996004260A1 (en) * 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pyridine derivatives useful in the treatment of the type ii diabetes
JP2000507216A (ja) * 1996-02-28 2000-06-13 グラクソ、グループ、リミテッド ＰＰＡＲ―γに対するアゴニスト活性を有する置換４―ヒドロキシフェニルアルカン酸誘導体
WO2003070686A1 (en) * 2002-02-21 2003-08-28 Asahi Kasei Pharma Corporation Substituted phenylalkanoic acid derivative and use thereof
JP2005015358A (ja) 2003-06-25 2005-01-20 Pharma Design Inc 摂食障害の治療に供される医薬組成物
WO2005051373A1 (ja) * 2003-11-26 2005-06-09 Takeda Pharmaceutical Company Limited 受容体機能調節剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0394440B1 (en) * 1987-10-20 1994-05-11 Otsuka Pharmaceutical Co., Ltd. Phenylcarboxylic acid derivatives
AU3959193A (en) * 1992-04-10 1993-11-18 Smithkline Beecham Plc Heterocyclic compounds and their use in the treatment of type II-diabetes
CA2139442A1 (en) * 1992-07-03 1994-01-20 David Haigh Heterocyclic compounds as pharmaceutical
GB9311644D0 (en) * 1993-06-05 1993-07-21 Smithkline Beecham Plc Novel compounds
GB9315148D0 (en) * 1993-07-22 1993-09-08 Smithkline Beecham Plc Novel compounds
AU6325899A (en) * 1998-10-21 2000-05-08 Dr. Reddy's Research Foundation New compounds, their preparation and use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996004260A1 (en) * 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pyridine derivatives useful in the treatment of the type ii diabetes
JP2000507216A (ja) * 1996-02-28 2000-06-13 グラクソ、グループ、リミテッド ＰＰＡＲ―γに対するアゴニスト活性を有する置換４―ヒドロキシフェニルアルカン酸誘導体
WO2003070686A1 (en) * 2002-02-21 2003-08-28 Asahi Kasei Pharma Corporation Substituted phenylalkanoic acid derivative and use thereof
JP2005015358A (ja) 2003-06-25 2005-01-20 Pharma Design Inc 摂食障害の治療に供される医薬組成物
WO2005051373A1 (ja) * 2003-11-26 2005-06-09 Takeda Pharmaceutical Company Limited 受容体機能調節剤

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
AM. J. CLIN. NUTR., vol. 73, 2001, pages 1019 - 1026
CURR DRUG TARGET CNS NEUROL DISORD, 2002
DIABETOLOGY, vol. 48, no. 9, 2005, pages 1700 - 13
DRUG, vol. 63, no. 12, 2003, pages 1785 - 97
ENDOCRINOLOGY, vol. 139, no. 5, 1998, pages 2363 - 8
NATURE MEDICINE, vol. 11, no. 1, 2005, pages 90 - 94
NATURE MEDICINE, vol. 11, no. 1, January 2005 (2005-01-01), pages 90 - 94
NEUROSCI BIOBEHAV REV., vol. 29, no. 8, 2005, pages 1361 - 73
NUTRITION, vol. 17, no. 3, 2001, pages 230 - 5
PHYSIOL BEHAV., vol. 83, no. 4, 2004, pages 617 - 21
See also references of EP2154131A4 *
USUI S. ET AL.: "Identification of novel PPERalpha ligands by the structural modification of a PPARgamma ligand", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 16, 2006, pages 3249 - 3254, XP005422618 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010104195A1 (en) * 2009-03-11 2010-09-16 Banyu Pharmaceutical Co.,Ltd. Novel isoindolin-1-one derivative
JP2012520240A (ja) * 2009-03-11 2012-09-06 Ｍｓｄ株式会社 新規イソインドリン−１−オン誘導体
US8362052B2 (en) 2009-03-11 2013-01-29 Msd K.K. Isoindolin-1-one derivative
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011161030A1 (de) 2010-06-21 2011-12-29 Sanofi Heterocyclisch substituierte methoxyphenylderivate mit oxogruppe, verfahren zu ihrer herstellung und ihre verwendung als gpr40 rezeptor modulatoren
WO2012004270A1 (de) 2010-07-05 2012-01-12 Sanofi Spirocyclisch substituierte 1,3-propandioxidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012004269A1 (de) 2010-07-05 2012-01-12 Sanofi ( 2 -aryloxy -acetylamino) - phenyl - propionsäurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012010413A1 (de) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylen-substituierte hydroxy-phenyl-hexinsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2014069963A1 (en) 2012-11-05 2014-05-08 Lg Life Sciences Ltd. Thioaryl derivatives as gpr120 agonists
US9447044B2 (en) 2012-11-05 2016-09-20 Lg Life Sciences Ltd. Thioaryl derivatives as GPR120 agonists
US10221138B2 (en) 2013-06-27 2019-03-05 Lg Chem, Ltd. Biaryl derivatives as GPR120 agonists
EP3628661A1 (en) 2013-06-27 2020-04-01 Lg Chem, Ltd. Biaryl derivatives as gpr120 agonists
JP2016527280A (ja) * 2013-08-09 2016-09-08 ファンダサウン オズワルド クルス ジフェニルオキシアルキルアミン誘導体およびアリールオキシアルキルアミン誘導体、薬学的組成物、慢性肺炎症性疾患を治療、予防、または阻止するための前記薬学的組成物の使用、ならびにそのような疾患を治療または予防するための方法
JPWO2021241659A1 (ja) * 2020-05-29 2021-12-02
WO2021241659A1 (ja) * 2020-05-29 2021-12-02 株式会社 Numt Ｆｆａｒ４を高発現させた脂肪細胞及びその使用
CN115698269A (zh) * 2020-05-29 2023-02-03 株式会社Numt 高表达ffar4的脂肪细胞及其使用
JP7411180B2 (ja) 2020-05-29 2024-01-11 株式会社Numt Ｆｆａｒ４を高発現させた脂肪細胞及びその使用

Also Published As

Publication number Publication date
US20100274022A1 (en) 2010-10-28
JPWO2008139879A1 (ja) 2010-07-29
EP2154131A1 (en) 2010-02-17
EP2154131A4 (en) 2011-09-21

Similar Documents

Publication Publication Date Title
WO2008139879A1 (ja) Ｇ蛋白質共役型レセプター抑制剤および医薬
NZ585460A (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta
WO2008083248A3 (en) Cyclopamine analogs
AU2008303600A8 (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
WO2008109181A3 (en) Metalloprotease inhibitors containing a heterocyclic moiety
WO2008064353A3 (en) 7,8-saturated-4,5-epoxy-morphinanium analogs
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
WO2008033798A3 (en) A pyrrolopyrazin as syk-kinase inhibitor
WO2008013838A3 (en) Pyridizinone derivatives
UA102817C2 (ru) Способ синтеза агомелатина
WO2006053255A3 (en) Novel betulin derivatives, preparation thereof and use thereof
WO2009016460A8 (en) Pyrazole compounds and their use as raf inhibitors
WO2007105058A3 (en) Pyrazole compounds
NO20084783L (no) Syntese av acylaminoalkenylenamider nyttige som substans P antagonister
WO2010105179A3 (en) Inhibitors of beta-secretase
WO2007084390A3 (en) Histone deacetylase inhibitors
MX2009008275A (es) Formas polimorficas de un inhibidor macrociclico del virus de la hepatitis c.
WO2008156094A1 (ja) ピリダジノン誘導体及びそれらを有効成分とするｐｄｅ阻害剤
UA102220C2 (ru) Способ синтеза агомелатина
WO2007029037A3 (en) Class iia histone deacetylase (hdac) substrate
WO2005005389A3 (en) Malonamide derivatives
WO2007117591A3 (en) Total synthesis of salinosporamide a and analogs thereof
UA97638C2 (ru) Способ синтеза ранелата стронция и его гидратов
WO2006108572A3 (en) Novel crystalline pharmaceutical product
WO2008093838A1 (ja) スルファモイル基を有するピリジルイミダゾリジン誘導体、およびその医薬としての使用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08752016

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009514078

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008752016

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12597570

Country of ref document: US